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Review Article 
Therapeutic Hemapheresis 
sheikh M. Saeed, MD* and B.K.S. Raman, MD" 
I n the 1950s, Adams, et al (1) introduced the method of 
phlebotomy fol lowed by selective removal of plasma 
and re-infusion of red cells for the treatment of hyper-
viscosity syndrome. When cell separators were intro-
duced in the 1960s, hemapheresis procedures became 
less cumbersome and time consuming. By careful differ-
ential centrif ugation, several liters of blood can be "p ro -
cessed" ex vivo, and the formed elements or plasma can 
be selectively removed. Because blood cell separators 
are efficient and relatively safe, the use of hemapheresis 
has markedly increased in the past decade. 
In this communicat ion we review important aspects of 
therapeutic hemapheresis which the clinician should 
consider when contemplating the benefit/r isk ratio of 
this therapy and its effectiveness. 
Terminology 
"Apairesos" and "aphairesis" are Greek and Latin words, 
respectively, and mean to take away or separate. The 
term pheresis, although partof the jargon, is linguistically 
incorrect and should not be used. The correct term is 
apheresis, and, depending upon the constituent being 
removed, the terminology becomes plasmapheresis, 
leukapheresis, etc. When large quantities of whole blood 
or plasma are removed, replacement with whole blood 
or plasma becomes necessary; in these situations, the 
applicable terms are blood exchange or plasma exchange. 
Equipment and Methodologies 
Commercially available cell separators utilize two dif-
ferent designs: continuous flow centrifugation (CEC) or 
intermittent f low centrifugation (IFC). The CEC system 
allows continuous withdrawal of small volumes of blood 
f rom the patient, separation of the blood constituents, 
and re-infusion into the patient of the desired material. 
The IFC system requires a set amount of blood to be 
withdrawn from the patient to fi l l the centrifuge bowl 
(usually 250 ml), differential centrifugation, and then 
re-infusion. The intermittent f low centrifuge, however, 
can be used quite efficiently with a single access site, 
including catheters, and the equipment is relatively 
lightweight and much more portable. Disadvantages of 
each system are partially offset by other design features. 
However, both systems are fully acceptable, self-contained 
units which eliminate the risks of transfusion errors and 
minimize many of the problems encountered with 
cumbersome manual apheresis procedures. 
Dynamics of Hemapheresis 
If it were possible to remove all of a patient's blood at 
one time and replace it with donor b lood, the patho-
logic material would fall to zero after one volume 
exchange. However, in practice, the efficiency of remov-
ing abnormal plasma constituents or formed elements 
depends upon the original concentration, mobility across 
intravascular and extravascular compartments, rate of 
synthesis of the constituent, and the mixing of the 
infused f lu id. Theoretically, a one volume plasma 
exchange should reduce the original plasma compo-
nents to 30% of the initial value and to approximately 
10% after the second plasma volume exchange (2). How-
ever, this relationship is only rarely observed for plasma 
proteins becauseof the rapid equi l ibrat ion between the 
intravascular and extravascular compartments; also, 55% 
of IgG and 25% of IgM are present in the extravascular 
compartment, and IgG is readily mobile across the two 
compartments. Further, since the efficiency of an 
exchange is greatest early in the procedure, many inves-
tigators perform limited exchanges of one volume per 
procedure in order to allow re-equil ibration or new 
synthesis of abnormal constituents and to make the 
second exchange more efficient. 
Replacement Solutions 
The most commonly used replacement solutions are 
crystalloids, 5% albumin, 5% plasma protein fraction 
(PPF), and fresh frozen plasma (FEP). Crystalloid solu-
tions may suffice when the exchange volume is small and 
when the patient is hyperproteinemic. In other situa-
Submit ted for publ icat ion: February 3,1983 
Accepted for publ icat ion: February 28,1983 
Department of Pathology, Hematopathology Divis ion, Henry Ford Hospital 
Address repr int requests to Dr. Saeed, Henry Ford Hospital,2799 W Grand Blvd, 
Detro i t , M l 48202 
47 
Saeed and Raman 
tions, it is essential to replace proteins to maintain col-
loid osmotic pressure and therefore the intravascular 
volume. Five percent albumin or PPF are easily available, 
do not require immunologic compatibi l i ty, and do not 
transmit hepatitis. However, because albumin or PPF do 
not provide essential coagulation factors, significant 
temporary reductions may occur after large volume 
plasma exchanges. After a four liter exchange using pro-
tein solutions, all coagulation factors are reduced; but 
within four hours. Factor IX, ristocetin cofactor, and 
Factor VIII procoagulant activity rapidly return to nor-
mal, whi le all other factors become normal within 24 
hours (3). Also reduced are C3, f ibr inogen, cholesterol, 
alkaline phosphatase, alanine aminotransferase, etc (4). 
Most of the constituent alterations are clinically incon-
sequential, and pre-exchange levels are restored within 
72 hours. 
Fresh frozen plasma does contain all the constituents, 
including coagulation factors and complement, but the 
availability of large amounts of EFP of the appropriate 
immunologic type can be a problem. In addi t ion, 
immunologic transfusion reactions do occur with EFP, 
and the transmission of hepatitis is a risk. Another disad-
vantage is that since EFP contains a fair amount of citrate 
anticoagulant, hypocalcemia occurs regularly when it is 
used as a replacement f lu id. However, this condit ion is 
readily reversed by slowing the infusion rate of FEP or by 
calcium supplementation. 
In general, it is rarely necessary, except in cases of 
th rombotic thrombocytopenic purpura (TTP), to totally 
replace plasma by donor plasma. In our own protocol , 
1,500 ml of crystalloid solution is given in lieu of the first 
1,000 ml of plasma, fol lowed by 5% albumin, volume for 
volume. At the end of the procedure, we transfuse two 
units of EFP to produce a modest increment of coagu-
lation factors, including f ibr inogen. Using this regimen, 
we have observed no volume or constituent-related 
problems in any of more than six hundred apheresis 
procedures. 
Theoretical Basis for the Beneficial Effects 
of Hemapheresis 
Hemapheresis is used in therapy for many diseases 
because it rapidly removes abnormal blood constitu-
ents, cellular or humoral, and leads to beneficial altera-
tions in the "mi l ieu int^r ieur." Antibodies, antigens, 
immune complexes, toxins, or an excessive number of 
cells can be removed efficiently if they are easily accessi-
ble via the vascular compartments, and normal blood 
components can also be infused, if warranted, at the 
same time. Removing noxious substances and replacing 
them by normal constituents may also induce immune 
modula t ion, improved ret iculoendothel ial funct ion, 
expeditious, functional recovery of affected organs, or 
increased response to conventional therapy. However, 
in most instances, hemapheresis procedures do not 
eliminate the serious underlying etio-pathologic mech-
anisms, which must betreated by alternate means. Thus, 
hemapheresis should be considered an excellent adjunc-
tive means for producing rapid alteration in the "mi l ieu 
int^r ieur" in conjunction with conventional therapy. 
Leukapheresis 
In patients with acute myelocytic or lymphocytic leuke-
mia, a rapidly rising white blood cell count above 
100,000/fjl can portend the development of the leuko-
stasis syndrome, often with fatal involvement of the cen-
tral nervous system and lungs. Cuttner, et al (5) have 
demonstrated that such patients benefit f rom cytore-
duct ion therapy in concert with chemotherapy. Leuka-
pheresis is very beneficial in the acute management of 
leukostasis complications, although the course of the 
disease is not altered (6). 
In chronic myelocytic leukemia (CML), the leukostasis 
syndrome occurs infrequently, and the white blood cell 
counts are usually much higher. Two patients with CML 
and cerebral leukostatic symptoms, one of whom was 
resistant to chemotherapy, were treated with granulocy-
tapheresis in our institution. The white blood cell count 
was reduced by 60% in both patients after three proce-
dures in one week. One of the patients responded to 
chemotherapy after the procedure, and the other patient, 
who was resistant to chemotherapy, responded to inter-
mittent granulocytapheresis during the next four months. 
In CML patients, white cell counts can be managed 
effectively for long periods by cytapheresis, and symp-
toms such as sweating, malaise, and pain of splenome-
galy can be rapidly relieved (6). Also, leukapheresis can 
significantly reduce organ size and control chemotherapy-
induced hyperuricemia. However, since bone marrow 
remission, prevention of blast crisis, or improved lon-
gevity have not been observed (7), long-term manage-
ment by leukapheresis is not indicated. 
Long-term cytoreduction therapy of patients with chronic 
lymphocytic leukemia (CLL) in order to prolong life has 
produced equivocal results (8,9). It is interesting to note, 
however, that Cooper, et al (10) report considerable 
reduction in the size of the lymph nodes and spleen, as 
well as an increase in hemoglobin level and platelets in 
patients with CLL and lymphocytic lymphoma after 
treatment with intensive cytapheresis. 
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Treatment of Sezary syndrome with cytapheresis has 
produced encouraging results. Winkleman, et al (11) 
have demonstrated clinical remission in patients treated 
by leukapheresis alone or in combination with low dose 
chemotherapy. Although some patients with Sezary 
syndrome become refractory to leukapheresis therapy 
after an initial clinical remission, it has been suggested 
that younger patients who have the disease may be the 
best candidates (12). In these patients, weekly leuka-
pheresis may be sufficient to maintain remission. 
Lymphocytapheresis 
Several diff icult diseases are now being treated by 
immune modulat ion, including lymphocytapheresis or 
lymphoplasmapheresis procedures. In rheumatoid arth-
ritis patients, Paulus, et al (13) have used thoracic duct 
drainage for short periods. Wright, et al (14) have shown 
that after such therapy the number of peripheral lym-
phocytes are decreased for several months, with specific 
reduction in the number of T-lymphocytes. In these 
patients, mitogen stimulation and skin reactivity are 
altered. Controlled treatment trials of rheumatoid arthritis 
patients by both lymphocytapheresis and lymphoplas-
mapheresis procedures confirm that significant, although 
modest, improvement occurred in the treatment group 
(12). In a larger study, Wallace, et al (15) treated 40 
rheumatoid arthritis patients using plasmapheresis, 
lymphapheresis,and lymphoplasmapheresis and reported 
that morning stiffness and the Ritchie index of synovitis 
were significantly improved in the lymphoplasmaphere-
sis group. 
Mul t ip le sclerosis is also diff icult to treat by conventional 
therapy. In a recent cooperative study cited by Gior-
dona, et al (16), 120 patients were treated by lymphocy-
tapheresis; 46% showed improvement in their Kurtzke 
disability rating, 1% deteriorated, and 53% remained 
stable. These results are very encouraging. 
Thrombocytapheresis 
The danger of hemorrhage or thrombosis in patients 
with platelet counts in excess of 1,000,000//uL is real. 
Whether the thrombocytosis is secondary or due to an 
underlying myeloproliferative process, thrombocyta-
pheresis procedures (17-19) can rapidly reduce platelet 
counts while other forms of therapy attack the underly-
ing problem; a three-hour procedure can induce a 30-
50% reduction in the peripheral platelet count. Aphere-
sis used alone is less successful in maintaining normal 
platelet counts over long periods. It is now well recog-
nized that prophylactic thrombocytapheresis for throm-
bocytosis is unwarranted, and this procedure should be 
reserved for patients who show marked thrombocytosis 
with impending thrombosis and hemorrhage. 
Erythrapheresis 
In sickle cell disease prophylactic or therapeutic red cell 
exchange has been attempted by many investigators 
(20-22). Prophylactic reduction of sickle hemoglobin in 
patients who are to receive general anesthesia is impor-
tant. In one of our patients, the sickle hemoglobin level 
was reduced to a third by 1.5 volume red blood cell 
exchange. The patient subsequently underwent success-
ful hip replacement surgery wi thout intraoperative or 
postoperative difficulties. 
Prophylactic erythrapheresis is also useful in children 
with sickle cell disease who have cerebral infarcts, since 
a second stroke can generally be prevented by this 
means (23). Exchange transfusions to abort sickle cell 
crisis have also been attempted, wi th encouraging 
results in some instances (12). We treated a young boy 
who developed priapism on two occasions. Automated 
erythrapheresis rapidly abated his symptoms, whereas 
other therapeutic measures were unsuccessful. 
Plasmapheresis 
Every new therapeutic modality goes through phases of 
enthusiastically expectant trials for management of a 
diverse group of diseases unt i l , finally, a consensus is 
reached about its true efficacy. In the past five to seven 
years, plasmapheresis has been tried for many condi-
tions in which conventional therapy has not been very 
effective or as a heroic last resort in grave conditions. 
However, consensus about its therapeutic effectiveness 
is now emerging, since the data base is rapidly increas-
ing, comparative figures of efficacy are becoming avail-
able, and several well control led trials are underway. 
Some of the conditions in which plasmapheresis is effec-
tive or shows considerable promise are described below. 
Paraproteinemias 
Symptomatic paraproteinemia is usually accompanied 
by systemic proliferation of immunocompetent clones 
of lymphoplasmacytic series (Waldenstrom's macroglo-
bulinemia, lymphoma, mult iple myeloma, heavy chain 
disease). Hyperviscosity syndrome, cryoglobulinemia, 
thrombocytopathy, inactivation of procoagulants, and 
acute renal failure are all caused by the unique physical, 
chemical properties of large asymmetrical paraprotein 
molecules. Since immunosuppressive therapy does not 
affect the immediate serologic concentration of para-
proteins, it has limited usefulness in the acute manage-
ment of hyperviscosity syndrome, whereas plasmapheresis 
can rapidly ameliorate all symptoms of the syndrome. A 
49 
Saeed and Raman 
review of three hundred procedures performed on 60 
patients by Russell and his colleagues (24) concluded 
that plasmapheresis is generally effective in rapidly 
relieving subjective symptoms with minimal side effects. 
Since serum viscosity is not a linear function of parapro-
tein concentrat ion, the removal of as little as 20% of the 
paraprotein volume may effectively reduce the viscosity 
by 50% or more (25). Removing larger quantities can 
promote prolonged, symptom-fee intervals, and patients 
have been maintained in symptom-free states for as long 
as 36 months using no other supportive therapy (26). 
Since most IgM is present in the intravascular compart-
ment and has limited mobil i ty across various compart-
ments, most can be removed in one volume exchange. 
Although plasma exchange is effective in reducing 
hyperviscosity, the paraprotein usually reaccumulates in 
the patient's b lood, depending upon the rate of produc-
tion.Therefore, most observers consider plasma exchange 
to be a temporizing strategy unti l definitive immuno-
suppressive therapy has taken effect. Opt imal doses of 
cytotoxic agents are not well tolerated by some patients, 
who may require intermittent plasmapheresis in con-
junct ion with cytotoxic agents. One of our patients with 
Waldenstrom's macroglobulinemia experienced a dras-
tic reduction in the serum viscosity level (up to one 
four th of the initial level) with obvious symptomatic 
relief after single volume exchanges (Fig. 1). 
Hyperviscosity, vasculitis (gangrene and necrotic ulcers), 
dermatopathy, and Reynaud's phenomenon are symp-
toms of cryoglobulinemia and may be diff icult to man-
age. Howert, et al (22) successfully used plasmapheresis 
on a patient who was refractory to conventional ther-
apy; the remission lasted more than 18 months. McLeod 
and Sassetti (28) reported significant improvement for 
three cryoglobulinemia patients who underwent plas-
mapheresis; their plasma was returned after being 
rapidly coo led to precip i tate c r yog lobu l i n , and 
cryoglobulin-free plasma was returned to the patients. 
In another study, five patients with Reynaud's disease 
who underwent five treatments at weekly intervals 
showed marked symptomatic improvement; in all but 
one case, their digital ulcers healed completely (29). 
Acute or chronic renal failure in mult iple myeloma is 
essentially caused by precipitation of Bence-Jones pro-
teins with destruction of the distal nephrons (30). Fifty 
percent of the circulating Bence-Jones proteins can be 
removed during a double volume plasma exchange. In 
renal failure patients who are unresponsive to diuretics, 
urine acidification, and chemotherapy, plasmapheresis 
can improve renal funct ion (30). However, further long-
term observations are needed to judge its therapeutic 
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Serum viscosity levels of patient wi th Waldenstrom's macroglobu-
linemia after plasma volume exchanges. 
effectiveness and the prognosis of patients with mye-
loma kidney. 
Autoimmune hemolytic anemia 
Patients with autoimmune hemolytic anemia, primary or 
secondary, warm or cold antibody type, confront life-
threatening situations if corticosteroids, immunosup-
pressive therapy, and splenectomy are not effective. 
Providing serologically compatible blood for these 
patients is extremely diff icult, and the transfused red 
cells are readily exposed to the lytic effects of antibodies 
circulating in the b lood. Intensive plasmapheresis to 
reduce the amount of circulating antibody has been 
attempted with some success in both the warm reactive 
and cold reactive antibody-mediated autoimmune hemo-
lytic anemias (31-35). In the cold agglutinin disease, 
apheresis procedures are diff icult to perform becauseof 
agglutination, sludging, and hemolysis of the red cells 
when the patient's blood is exposed to a lower room 
temperature in the centrifuge bowls; blood warmers 
along the in-f low and out-f low lines are beneficial in 
these instances. Although hemagglutinating antibody 
titers are significantly reduced, and the hemolytic pro-
cess is improved, antibody titers return to previous levels 
rather rapidly unless immunosuppressive therapy be-
gins to take effect. 
Idiopathic thrombocytopenic purpura (ITP) 
Because patients with ITP respond variously and unpre-
dictably to corticosteroids and/or splenectomy, it is dif-
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f icult to asess the role of plasmapheresis in their treat-
ment. Branda, et al (36) described the response in two of 
three ITP patients. One was a 21-year-old man who had 
been in good health when he was admitted with a plate-
let count of 4,000//uL. The patient did not respond to 
high dose steroids (200 mg per day) and showed only a 
transient increase in his platelet count after splenec-
tomy. Several days later, his hemoglobin level dropped, 
and there was evidence of intra-abdominal hemor-
rhage. He did not respond to treatment with vincristine 
and steroids, but his platelet count increased after plas-
mapheresis on two occasions. Thereafter, the platelet 
counts gradually became normal. Branda, et al (36,37) 
cited cases in which demonstrable antiplatelet antibody 
titers before plasmapheresis were reduced by 50% after 
a single session, and platelet counts increased by fifty to 
sixty-fold within several hours of the procedure. In a 
larger group of nine consecutive patients with acute ITP 
and five patients with chronic ITP, Marder et al (38) 
reported that the acute cases had a good response wi th-
out the need for splenectomy, whereas the patients suf-
fering f rom chronic ITP did not respond at all. In our 
institution four ITP patients, two of whom were consi-
dered chronic, received plasmapheresis (Fig. 2). It would 
thus appear that a trial of plasma exchange in ITP 
patients is warranted before splenectomy is performed. 
Thrombotic thrombocytopenic pupura 
The pathogenesis ofthis fascinating disease now revolves 
around the possibility of immune complex deposition 
on vessel walls and platelet membranes and the possibil-
ity that there is a missing plasma factor such as prostacyc-
l in , PGI2 (39,40). Absence of PGI2, which is a potent 
inhibi tor of platelet aggregation, leads to platelet con-
sumption and underlying vascular endothelial damage. 
Conventional therapy using corticosteroids, antiplatelet 
agents, cytotoxic agents, and splenectomy has been 
tried for several years, but the mortality rates with con-
ventional therapy still range between 72% at three 
months to 93% by one year (39). The use of plasma 
exchange as adjunctive therapy has been tried in more 
than 60 patients, and 67% achieved remission of three 
years or more. In these cases, recovery occurred after as 
little as one exchange of two liters of plasma, while other 
patients required up to 28 liters over several sessions. 
Recent reports indicate that FEP infusion alone may be 
effective in the therapy of TTP (41), since normal plasma 
inhibits the platelet aggregating factor present in the 
plasma of TTP patients. However, it should be recog-
nized that infusion of massive amounts of plasma wil l 
cause volume overload in most patients. Wenz and Bar-
land (42) speculate that the plasma exchange is effective 
in patients with TTP, serving both to remove a pathologic 
plasma constituent whi le simultaneously providing the 
necessary therapeutic material in adequate doses. The 
availability of PGI 2 or other missing plasma factors in TTP 
patients would be of considerable benefit if the def i-
ciency of such factors is the major contr ibut ing factor for 
TTP. One of our patients with central nervous system 
symptoms who was diagnosed as having TTP showed 
significant improvement of neurologic and other symp-
toms after plasma exchange with EFP. Later, the patient's 
platelet counts became normal with infusion of FEP. 
Rho hemolytic disease 
The rate of al lo-immunization of childbearing women 
has markedly decreased since the introduction of Rho 
immunoglobul in injections. However, a number of allo-
immunized women still remain at a high risk of fetal 
morbidity and mortality if intra-uterine hemolysis is 
conf i rmed by the 26th gestational week. Studies by 
Frazier, et al (43), involving 44 Rh-immunized patients, 
and by Graham-Pole, et al (44), involving eight severely 
affected women, are very encouraging in that most can 
be brought to term successfully. In both studies, ma-
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Plasmapheresis in four patients w i th idiopathic thrombocytopenic 
p u r p u r a . ' ' Female, 83; one year du ra t ion ; plasma exchange on day 1 
and 2; normal platelet count on last visit — Female, 20; one month duration 
(steroids and vincrist ine); plasma exchange on days1,2and3. l 11 Male , 
46; one month durat ion (steroids); plasma exchange on days 1 and 2; 
platelet count normal after splenectomy. — Female, 69; five years' 
durat ion (steroids, Oncovin, and Cytoxan w i thou t ef fect) ; splenectomy 
done wi thout beneficial ef fect ; massive b leeding contro l led by single 
apheresis; good response to steroids fo l lowing apheresis; platelet 
count after four months - lOO.OOO/mm^ and rising. 
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ternal antibody titers were significantly reduced after 
plasmapheresis. 
Renal allograft rejection 
Rifle, et al (45) have demonstrated the reduction of HLA 
antibodies using plasmapheresis in four of five patients 
with active rejection episodes. Circulating immune 
complexes were also removed, although titers of anti-
bodies to B-lymphocytes did not change. Ina large series 
of 37 patients, all patients were treated with corticoste-
roids and graft irradiation, and 15 were treated with 
plasma exchange also (46). Six patients in the control 
group and one in the plasmapheresis group rejected 
their grafts. Studies by Slapak, et al (47), Naik, et al (48), 
and Cardella, et al (46,49) show beneficial effects of 
plasma exchange therapy in conjunction with standard 
anti-rejection regimens. However, Power, et al (50) and 
Kirubakaran, et al (51) found no benefit f rom plasma 
exchange therapy in treating transplant rejection. Thus, 
it would appear that further, appropriately control led 
protocols are needed to determine the cases in which 
plasma exchange can be beneficial. 
Post-transfusion purpura 
Two percent of the general population is PLA-1 antigen 
negative, and they may develop anti-PLA-1 antibodies if 
transfused with PLA-1 positive platelets. This antibody 
not only reacts with the transfused platelets, but it also 
produces immune complexes which bind to the recip-
ients' own platelets. The antibody, which is IgG, is 
responsible for post-transfusion purpura, and plasma 
exchange therapy is the treatment of choice in these 
cases (52,53). 
Myasthenia gravis 
Auto immune antibodies, usually IgG, to the neuromus-
cular acteylcholine receptors are responsible for most 
symptoms of the myasthenia syndrome. There is an 
inverse relationship between the acetylcholine receptor 
antibody levels and symptoms (54). Recently, patients 
with myasthenia gravis who have failed to respond to 
steroids, thymectomy, and anticholinesterase drugs have 
received plasma exchange therapy, with or wi thout the 
continuation of steroids and immunosuppression (55). 
Among various studies, 75% of these patients showed a 
rapid clinical response lasting f rom three weeks to eight 
months (55-58). In Tindall's series of 57 patients, 43 
showed good response (56). Tindall observed that the 
initial benefit was usually detectable after the second 
exchange, and the maximal benefit was usually seen two 
days after the sixth plasma exchange was completed. 
Patients whose disease was of short duration responded 
properly to the plasma exchange, but patients with 
chronic, severe disease, who may have developed post-
synaptic destructive changes, responded only occasion-
ally and were uniformly dependent upon exchanges for 
years. Of the 60 patients treated by Dau (55), 48 received 
corticosteroids, all but one received azathioprine, and 
plasma exchanges were done weekly. Of these patients, 
39 had an earlier thymectomy, and 42 had received cor-
ticosteroid therapy. Only one of the 60 patients showed 
no improvement, 15 showed modest improvement, and 
12 patients had no residual weakness. 
Despite unanswered questions about the typeof patient 
who would respond to plasma exchange therapy, the 
type of protocol , and the length of expected remission, 
the early use of plasma exchange in the therapy of myas-
thenia gravis wil l eventually be preferred to continued 
long-term use of corticosteroids or other immunosup-
pressive cytotoxic therapy. 
Guillain-Barr^ syndrome 
Several reports of dramatic, albeit short-l ived, remis-
sions induced by plasma exchange are in the literature 
(59-62). Recently, Tindall (63) analyzed his experience 
with seven patients with acute inflammatory demyelinat-
ing polyneuropathy who were judged to have Grade IV 
disease or worse. In three of seven instances, patients 
improved with in the first 14 days after plasma exchange 
was initiated. All patients improved within six months. 
Six patients with relapsing inflammatory demyelinating 
polyneuropathy were also studied, and four of the six 
improved by two clinical grades. Two of the four 
responding patients became dependent on apheresis 
and required maintenance procedures at intervals of 
one to four weeks. Eight patients with slowly progressive 
chronic inflammatory demyelinating polyneuropathy 
were treated by plasma exchange, and two showed early 
response. In five of the eight, sustained control of the 
disease with plasmapheresis and/or immunosuppres-
sive therapy could be achieved. Tindall concludes that in 
Guillain-Barr^ syndrome a trial with plasmapheresis is 
warranted, although failure to improve during an initial 
period of intense plasmapheresis precludes improve-
ment during continued or subsequent exchanges. 
Systemic lupus erythematosus (SLE) 
Circulating autoreactive antibodies and immune com-
plexes in this disease along with disengorgement of the 
reticuloendothelial system can logically be treated by 
plasma exchange therapy. In several published reports 
(64-67), 50% of the patients showed clinical improve-
ment as a result of plasmapheresis, lasting between ten 
days and one month. Clinical and immunologic findings 
rebounded if no other therapeutic modalities such as 
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corticosteroids and/or azathioprine were used in con-
junct ion with plasmapheresis. However, reports (68) 
indicate that plasmapheresis in conjunction with cort i -
costeroids or cytotoxic agents produced considerable 
clinical and immunologic improvement, sometimes of a 
prolonged nature. Jones (68) believes that plasmaphere-
sis might be considered a potentially valuable adjunct in 
the treatment of patients with severe SLE, when high 
doses of corticosteroids have failed. In these patients, 
the best results can be expected f rom a combined regi-
men of plasmapheresis and cyclophosphamide. Since 
there are many variables in the reported cases, a ran-
domized prospective trial of plasmapheresis in patients 
with severe SLE glomerulonephrit is has been initiated 
under Dr. E.J. Lewis of Rush Presbyterian-St. Luke's Med -
ical Center in Chicago, which involves many other col-
laborating centers, including Henry Ford Hospital. 
Renal diseases 
Circulat ing immune complexes and/or glomerular 
basement membrane (GBM) antibodies cause severe 
and progressive immunologically-mediated inflamma-
tory destruction of renal parenchyma. In a few patients 
with anti-GBM nephritis and Goodpasture's syndrome, 
the disease may be self l imited, with rapid fall of anti-
GBM antibody titers; but in 80% o f t he cases, end-stage 
renal insufficiency develops. In these cases plasma 
exchange has been used to: 1) remove circulating 
immune complexes and/or anti-GBM antibodies; 2) 
remove GBM antigens which may be released by the 
destructive inflammatory process and which, in turn, 
enhance autoimmune processes; 3) reduce plasma levels 
of inflammatory mediators such as f ibr inogen, comple-
ment, etc; 4) disengorge the reticuloendothelial system 
and mobil ize deposits from other areas such as the 
alveolar bed; 5) induce rebound proliferative activity of 
auto-antibody producing clones which may be kil led by 
concomitant immunosuppressive therapy. 
Several investigators have reported the usefulness of 
plasmapheresis in renal diseases due to antibodies or 
circulating immune complexes (69-73). Recent reports 
of control led studies by Pusey and Lockwood (73) are 
encouraging. They studied 44 patients with anti-GBM 
disease; 22 were already oliguric or anuric and did not 
respond to plasma exchange, but 16 of the 22 remaining 
patients showed marked improvement. They also report-
ed that 34 of 41 patients with immune complex rapidly 
proliferative glomerulonephrit is improved on a plasma 
exchange regimen. Remarkably, 13 of 19 oliguric or 
anuric patients improved. 
Other Diseases 
Many other conditions have been treated by plasma 
exchange with varying success. Promising results are 
reported in conditions such as inhibitors to coagulation 
Factor VIII (74-76), Refsum's disease (77,78), familial 
hypercholesterolemia (79-82), diabetic hypertrigly-
ceridemia (80,82), primary biliary cirrhosis (83,84), insulin 
resistant diabetes (85), pemphigus vulgaris (86-87), pso-
riasis (88), dermatomyositis (89), carcinomatosis (90-92), 
poisonings by Paraquat (93), by methylparathion (94), or 
by mushrooms (95,96). 
Summary 
Therapeutic hemapheresis procedures are increasingly 
being used to rapidly remove circulating and mobiliza-
ble deleterious materials. Procedures are safe and effec-
tive in appropriately monitored patients. Although in 
some instances the measurable parameters and the 
patient's condit ion change dramatically, the effects of 
hemapheresis are usually temporary, and concomitant 
specific drug therapy directed at the primary disease is 
necessary. Nevertheless, evidence is mult iplying that 
apheresis procedures can benefi t many previously 
therapy-resistant conditions. Immune modulat ion, the 
ability to interfere with re- introduct ion or resynthesis of 
substances, and the additional t ime the procedure 
allows for end-organ repair or regeneration, are com-
pell ing reasons for performing apheresis in carefully 
selected situations. 
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